Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00987649 · ClinicalTrials.gov registry record
Ovarian Cancer Risk Estimation in Patients With Pelvic Mass
A clinical trial, sponsored by Fujirebio Diagnostics.
- Completed
- Registry status
- 512
- Enrollment target
NCT00987649: Completed study, sponsored by Fujirebio Diagnostics.
NCT00987649 is a clinical trial that has completed, run by Fujirebio Diagnostics. The registered enrollment target is 512 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00987649 has completed, sponsored by Fujirebio Diagnostics.
- COMPLETED
- Registry status
- 512 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the Risk of Ovarian Cancer Algorithm (ROMA) is effective in the determination of a woman's risk of cancer when she is scheduled to have surgery to remove a pelvic mass. After Informed Consent is obtained, an Initial Cancer Risk Assessment will be made. A blood sample will be collected within 30 days of the surgical procedure. Results of the surgical procedure will be collected and analyzed against the CA125 and HE4 results used in the calculation of the ROMA.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 512 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-09 |
What the finished NCT00987649 record still lists
NCT00987649 is an observational study that tracks outcomes without assigning an intervention. The registered 512 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00987649 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00987649 about?
NCT00987649 is a clinical study titled "Ovarian Cancer Risk Estimation in Patients With Pelvic Mass". The purpose of this study is to determine whether the Risk of Ovarian Cancer Algorithm (ROMA) is effective in the determination of a woman's risk of cancer when she is scheduled to have surgery to remove a pelvic mass. After Informed Consent is obtained, an Initial Cancer Risk Assessment will be ma...
What is the current status of trial NCT00987649?
This trial is currently completed. The enrollment target is 512 participants. The study started on 2009-10. Estimated completion is 2010-09.
Who is sponsoring clinical trial NCT00987649?
This trial is sponsored by Fujirebio Diagnostics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05005403 · 512 participants · Phase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
- NCT05337410 · 512 participants · NA
YES: Innovative Discussion for Engagement, Achievement, and Service
- NCT06096259 · 512 participants · Phase 2
Preventing Injured Knees From osteoArthritis: Severity Outcomes
- NCT05691244 · 514 participants · Phase 3
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia